Updates are available Correction dated 2021-03-08

Article History

Received: 4 June 2020

Accepted: 18 November 2020

First Online: 9 December 2020

Change Date: 8 March 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s12885-021-07999-y

Ethics approval and consent to participate

: Approval was obtained from the local research and audit committee (Royal Marsden Hospital).

: Not applicable.

: DC Collins: Advisory board for Seattle genetics, GenMab, Merck, AZD. Honoraria from Genmab, Pfizer, Roche, Eli Lilly, AZD. Travel funding from Roche, AZD, BMS, Genmab. These are outside the submitted work.R Sundar: Advisory board for BMS, Merck, Eisai, Bayer, Taiho. Honoraria for talks from MSD, Eli Lilly, BMS, Roche, Taiho. Travel funding from Roche, Astra Zeneca, Taiho, Eisai. Research funding from Paxman Coolers, MSD. These are outside the submitted work.A Constantinidou: None declared.D Dolling: None declared.TA Yap: Research support from AstraZeneca, Bayer, Clovis, Constellation, Cyteir, Eli Lilly, EMD Serono, Forbius/Formation Biologics, F-Star, GlaxoSmithKline, Genentech, ImmuneSensor, Ipsen, Jounce, Karyopharm, Kyowa, Novartis, Pfizer, Ribon Therapeutics, Regeneron, Sanofi, Seattle Genetics, Tesaro, and Vertex Pharmaceuticals. Consultancies with Almac, Aduro, AstraZeneca, Atrin, Axiom, Bayer, Calithera, Clovis, Cybrexa, EMD Serono, F-Star, Guidepoint, Ignyta, I-Mab, Jansen, Kyn Therapeutics, Merck, Pfizer, Roche, Seattle Genetics, and Zai Labs. These are outside the submitted work.S Popat: Honoraria from BMS, Roche, Takeda, AstraZeneca, Pfizer, MSD, EMD Serono, Guardant Health, AbbVie, Boehringer Ingelheim, Medscape, Tesaro, Paradox, Incyte, OncLive. Direct funding from Elsevier. These are outside the submitted work.MER O’Brien: Advisory boards for MSD, Abbvie, BMS, BI, Pierre Fabre. These are outside the submitted work.U Banerji: Is a recipient of an NIHR Research Professorship Award and has received CRUK funding: Cancer Research UK Scientific Executive Board, Cancer Research UK Centre Award. Cancer Research UK Drug Discovery Committee – Programme Award. These are outside the submitted work.J de Bono: Has served on advisory boards and received fees from many companies including Astra Zeneca, Astellas, Bayer, Boehringer Ingelheim, Cellcentric, Daiichi, Genentech/Roche, Genmab, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Menarini/Silicon Biosystems, Orion, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Vertex Pharmaceuticals. He is an employee of The ICR, which have received funding or other support for his research work from AZ, Astellas, Bayer, Cellcentric, Daiichi, Genentech, Genmab, GSK, Janssen, Merck Serono, MSD, Menarini/Silicon Biosystems, Orion, Sanofi Aventis, Sierra Oncology, Taiho, , Pfizer, Vertex, and which has a commercial interest in abiraterone, PARP inhibition in DNA repair defective cancers and PI3K/AKT pathway inhibitors (no personal income). He was named as an inventor, with no financial interest, for patent 8,822,438. He has been the CI/PI of many industry sponsored clinical trials. JDB is a National Institute for Health Research (NIHR) Senior Investigator. These are outside the submitted work.J Lopez: Research grant funding from Roche, Basilea, and Genmab. These are outside the submitted work.N Tunariu: None declared.A Minchom: Has served on advisory boards and received fees from Merck, Faron, Novartis, Bayer, Janssen. These are outside the submitted work.